These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 11721888)

  • 1. Sympathetic nervous system and insulin resistance: from obesity to diabetes.
    Esler M; Rumantir M; Wiesner G; Kaye D; Hastings J; Lambert G
    Am J Hypertens; 2001 Nov; 14(11 Pt 2):304S-309S. PubMed ID: 11721888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sympathetic system and hypertension.
    Esler M
    Am J Hypertens; 2000 Jun; 13(6 Pt 2):99S-105S. PubMed ID: 10921528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure.
    Esler M; Kaye D
    J Auton Nerv Syst; 1998 Oct; 72(2-3):210-9. PubMed ID: 9851571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High blood pressure management: potential benefits of I1 agents.
    Esler M
    J Hypertens Suppl; 1998 Aug; 16(3):S19-24. PubMed ID: 9747906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Insulin resistance and arterial hypertension].
    Weidmann P; Müller-Wieland D; de Courten M; Krone W
    Herz; 1995 Feb; 20(1):16-32. PubMed ID: 7713473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation in the effects of the angiotensin II receptor blocker class on autonomic function.
    Esler M
    J Hypertens Suppl; 2002 Jun; 20(5):S13-9. PubMed ID: 12184059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice.
    Esler M; Lambert G; Brunner-La Rocca HP; Vaddadi G; Kaye D
    Acta Physiol Scand; 2003 Mar; 177(3):275-84. PubMed ID: 12608997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance.
    Masuo K; Rakugi H; Ogihara T; Esler MD; Lambert GW
    Curr Diabetes Rev; 2010 Mar; 6(2):58-67. PubMed ID: 20034369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
    Hall JE; do Carmo JM; da Silva AA; Wang Z; Hall ME
    Circ Res; 2015 Mar; 116(6):991-1006. PubMed ID: 25767285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of sympathetic nervous system and neuropeptides in obesity hypertension.
    Hall JE; Brands MW; Hildebrandt DA; Kuo J; Fitzgerald S
    Braz J Med Biol Res; 2000 Jun; 33(6):605-18. PubMed ID: 10829088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion.
    Esler M; Lux A; Jennings G; Hastings J; Socratous F; Lambert G
    J Hypertens; 2004 Aug; 22(8):1529-34. PubMed ID: 15257176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease.
    Esler M; Kaye D
    J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S1-7. PubMed ID: 11346214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors that influence the risk of hypertension in obese individuals.
    Coatmellec-Taglioni G; Ribière C
    Curr Opin Nephrol Hypertens; 2003 May; 12(3):305-8. PubMed ID: 12698070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sympathetic nervous system alterations in human hypertension.
    Grassi G; Mark A; Esler M
    Circ Res; 2015 Mar; 116(6):976-90. PubMed ID: 25767284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity, hypertension, and sympathetic nervous system activity.
    Corry DB; Tuck ML
    Curr Hypertens Rep; 1999; 1(2):119-26. PubMed ID: 10981052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance in systemic hypertension: pharmacotherapeutic implications.
    Mediratta S; Fozailoff A; Frishman WH
    J Clin Pharmacol; 1995 Oct; 35(10):943-56. PubMed ID: 8568012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension in obesity and NIDDM. Role of insulin and sympathetic nervous system.
    Daly PA; Landsberg L
    Diabetes Care; 1991 Mar; 14(3):240-8. PubMed ID: 2044439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rilmenidine sympatholytic activity preserves mental and orthostatic sympathetic response and epinephrine secretion].
    Esler M; Lux A; Jennings G; Hastings J; Socratous F; Lambert G
    Arch Mal Coeur Vaiss; 2004; 97(7-8):786-92. PubMed ID: 15506067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance, hyperinsulinemia and hypertension.
    Weidmann P; de Courten M; Böhlen L
    J Hypertens Suppl; 1993 Dec; 11(5):S27-38. PubMed ID: 8158379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology and treatment of the obesity-related arterial hypertension.
    Kolanowski J
    Acta Clin Belg Suppl; 1992; 14():18-25. PubMed ID: 1604957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.